Chris Garabedian, President and CEO Sarepta Therapeutics (SRPT), announced that the Phase IIb clinical study on its first product, eteplirsen, will have its results submitted to the FDA by the end of the year, with a launch slated for mid next-year if approved. He was speaking at the Canaccord Genuity 34th Annual Growth Conference at the Intercontinental Hotel in Boston, Massachusetts.
Sarepta Therapeutics targets therapies for the RNA molecule. The company’s lead drug development program is for Duchenne muscular dystrophy (DMD), which affects mostly boys and is 100% fatal, with most passing in their 20s. The Phase II tests for eteplirsen show it slows the decline in walking ability for DMD patients who take a six-minute walk test (6MWT). It also stabilized respiratory muscle function as assessed by pulmonary function tests. It is now in the long-term phase in which patients are continued to be followed for safety and clinical outcomes.
FOR THE LATEST TWST BIOTECHNOLOGY REPORT, CLICK HERE.
Cambridge, Massachusetts-based Sarepta has 180 employees, two research facilities and recently purchased a manufacturing plant as it scales up for the potential release of eteplirsen. Garabedian said Sarepta has $284 million in cash and cash equivalents.
The company has produced mid-scale batches of eteplirsen, and will advance that to large scale commercial batches in time for a potential commercial launch next year. It also has started studies with follow-on drugs in its pipeline, which can be modified to adapt to genetic subtypes.
FOR THE FULL PRESENTATION, CLICK HERE.
Astria Therapeutics (NASDAQ:ATXS), Biomea (NASDAQ:BMEA) and Sarepta (NASDAQ:SRPT): Three Biotech Stocks Ready to Pop
April 12, 2023
Sarepta Therapeutics (SRPT) Muscular Dystrophy Franchise Significantly Undervalued
April 30, 2013
Sarepta Therapeutics Inc’s (SRPT) Technology Shows Dramatic Results as DMD Patients Regain Functions
May 17, 2013
Matt Flake, President and CEO of Q2 Holdings Inc (QTWO), Presents at Canaccord Genuity Global Growth Conference
August 15, 2014
Jim Corbett, President and CEO of Alphatec Holdings Inc. (ATEC), Presents at Canaccord Growth Conference
August 18, 2014
